ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy

ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy

Abstract Despite advancements in treating metastatic melanoma, many patients exhibit resistance to targeted therapies. Our study focuses on ATP1A1, a sodium pump subunit associated with cancer development. We aimed to assess ATP1A1 prognostic value in melanoma patients and examine the impact of its...

Full description

Bibliographic Details
Main Authors: Laura Soumoy, Aline Genbauffe, Lena Mouchart, Alexandra Sperone, Anne Trelcat, Léa Mukeba-Harchies, Mathilde Wells, Bertrand Blankert, Ahmad Najem, Ghanem Ghanem, Sven Saussez, Fabrice Journe
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Cancer Cell International
Subjects:
Melanoma
Resistance
ATP1A1
Sodium pump
Cardiotonic steroid
Bufalin
Online Access:https://doi.org/10.1186/s12935-023-03196-y

Internet

https://doi.org/10.1186/s12935-023-03196-y

Similar Items